News
PM Modi at the Red Fort: Indian Pharma Companies Must Enter the Global Top 5 — Pharmacy of the World to Innovation Hub on 80th Independence Day
By Mustafa Shariff, Editor in Chief · August 19,2026 · 2 mins read
Summary
- PM Modi's 80th Independence Day Challenge: Indian Pharma Must Enter the Global Top 5 — Pharmacy of World to Innovation Hub
- PM Modi's August 15 Red Fort address set an ambitious target: one or two Indian pharma companies to enter the global top 5. India currently ranks 3rd by volume, 11th by value. 50+ high-end medical devices now made under PLI. Pharma market: $60B → $130B by 2030.
"We have done significant work in the pharmaceutical sector, but the need of the hour is for one or two Indian companies to feature prominently among the global top five pharmaceutical companies. India must secure its place there. Our pharma sector is moving from being the pharmacy of the world to becoming a hub of innovation — with greater emphasis on research and development, biologics, biosimilars, and next-generation therapies. This is the ambition that befits a Viksit Bharat."
Prime Minister Narendra Modi delivered India's 80th Independence Day address from the Red Fort on August 15, 2026, setting among the most ambitious pharmaceutical targets ever articulated by an Indian Prime Minister: he called on Indian pharmaceutical companies to secure a place among the world's five largest pharmaceutical companies — asking India's sector to make a step-change from its current position of 3rd globally by volume and 11th globally by value.
The global top 5 pharmaceutical companies by revenue — Johnson & Johnson, Roche, AbbVie, Pfizer, and Novartis, each generating revenues exceeding $40-50 billion annually — are all multinational corporations with century-old histories, global regulatory presence, and diversified branded product portfolios across multiple therapeutic areas. India's largest pharmaceutical company by revenue, Sun Pharma, generates approximately $5-6 billion annually — one-eighth to one-tenth the revenue of the top 5.
The Innovation Hub Framing
PM Modi's Red Fort address frames India's pharmaceutical ambition in terms that go beyond manufacturing scale: from pharmacy of the world to hub of innovation, with greater emphasis on research and development, biologics, biosimilars, and next-generation therapies. This framing — positioning innovation capability rather than manufacturing volume as the defining aspiration — is consistent with BioSpectrum India's 'Great Pharma Pivot' analysis (covered BHC Media July 30 edition) and with the investment data showing 10-plus novel drug assets and $731 million in pharmaceutical innovation investments (covered July 17 edition).
The PLI Milestones: 50+ High-End Medical Devices
On the medtech dimension, the Prime Minister highlighted that more than 50 high-end medical devices have started being manufactured in India under the Production Linked Incentive (PLI) scheme — a tangible output measure of the import substitution ambition that BHC Media has covered across multiple editions (AiMeD SMDI, EPMED-MSME MoU, Medical Device Amendment Rules). India's medtech market, valued at $15-16 billion and growing at 12% annually, is the 4th largest in Asia and among the top 20 globally.
The Fortune 500 Ambition
Alongside the pharmaceutical top 5 target, PM Modi called for India to have 50 companies listed in the Fortune 500 global ranking — a target that, given India currently has approximately 8-9 companies in the Fortune 500, requires either dramatically higher revenue scale for India's current companies or the emergence of entirely new companies of global scale. Healthcare companies would need to be a significant component of India's Fortune 500 representation at the scale required.
BHC Perspective
At Bengaluru Health Community, PM Modi's Independence Day pharmaceutical top 5 ambition is the political articulation of the commercial trajectory that BHC Media has been documenting throughout 2026. Sun Pharma's Organon acquisition (top-25 global pharma), Biopharma SHAKTI's 100 biologics target, NITI Aayog's $691 billion bioeconomy roadmap, and the Great Pharma Pivot — all are steps on the journey toward the destination PM Modi named on August 15. The government has set the ambition. The ecosystem is building toward it.
Frequently Asked Questions
Q: What did PM Modi say about pharma on Independence Day?
A: Called for one or two Indian pharmaceutical companies to enter the global top 5 by revenue, from India's current position of 3rd globally by volume and 11th by value. Framed India's pharma transition as 'pharmacy of the world to hub of innovation' with emphasis on R&D, biologics, biosimilars, and next-generation therapies.
Q: How far is India from the global pharma top 5?
A: The global top 5 (J&J, Roche, AbbVie, Pfizer, Novartis) each generate $40-50B+ annually. India's largest company Sun Pharma generates ~$5-6B — roughly one-eighth the scale of a top-5 company. Sun Pharma's $11.75B Organon acquisition (closing Q4 FY27) will add significant revenue but still leave a significant gap.
Q: What PLI milestone did PM Modi highlight?
A: 50-plus high-end medical devices are now being manufactured in India under the PLI scheme. India's medtech market: $15-16 billion, growing 12% annually, 4th largest in Asia, top 20 globally.